Per Pfeiffer

Researcher Next ID · RN-038758

Researcher · Biochemistry, Genetics and Molecular Biology

University of Southern Denmark

Odense, Denmark

Accepting doctoral researchersFunding unknown

Works count: 539
Citation count: 22,448
H-index: 61
i10-index: 204

Research interests

Biochemistry, Genetics and Molecular Biology

Medicine

Colorectal Cancer Treatments and Studies

Pancreatic and Hepatic Oncology Research

Gastric Cancer Management and Outcomes

Cancer Treatment and Pharmacology

Cancer Genomics and Diagnostics

Publications

Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.08.009
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00515-6
Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
Journal of Clinical Oncology · 2022 · https://doi.org/10.1200/jco.22.01134
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30555-6
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1908075
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(18)30791-5
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Annals of Oncology · 2016 · https://doi.org/10.1093/annonc/mdw235
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mds236
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
The Lancet Oncology · 2010 · https://doi.org/10.1016/s1470-2045(10)70130-3

Current projects

No projects listed.